August 17, 2026
If you're considering Spravato® for depression, one of your first practical questions may be: Will my insurance cover it?
For many eligible patients, insurance may cover at least part of the cost of Spravato® (esketamine). However, coverage isn't automatic, and requirements can vary considerably between insurance companies and individual plans.
Insurers may consider your diagnosis, previous antidepressant treatments, medical necessity, prior authorization requirements, deductible, copay, and other plan-specific factors.
At Saltmeadow Psychiatry in Savannah, GA, patients considering Spravato® can receive a psychiatric evaluation to determine whether the treatment may be clinically appropriate. Insurance benefits and authorization requirements can then be reviewed before treatment begins.
Many commercial insurance plans may provide coverage for Spravato® when a patient meets the insurer's eligibility and medical-necessity requirements.
Spravato® has FDA-approved psychiatric indications, which distinguishes it from IV ketamine when ketamine is used off-label to treat depression.
However, FDA approval does not mean every insurance company automatically covers treatment for every patient.
Your specific coverage depends on your individual health plan.
Spravato® commonly requires prior authorization.
Prior authorization means your insurance company reviews certain information before agreeing to cover the treatment.
Depending on the plan, an insurer may request documentation related to:
Requirements vary between insurers, so one patient's approval process may differ from another's.
For patients being evaluated for treatment-resistant depression, previous treatment history can be especially important.
Your psychiatrist may need to document which antidepressants you've tried, how you responded, whether side effects occurred, and whether those medications were taken at appropriate doses and for sufficient periods.
This information serves two purposes.
First, it helps your psychiatrist determine whether Spravato® is clinically appropriate.
Second, it may provide documentation an insurance company requires when reviewing authorization.
Providing an accurate medication and treatment history during your initial evaluation can therefore make the process easier.
There isn't one universal price.
Your out-of-pocket expense can depend on:
Two patients with the same insurance company can have different costs because their individual plans and benefits may be different.
For that reason, patients should verify their benefits rather than relying on cost estimates found online.
Having insurance coverage doesn't necessarily mean treatment will initially have a low out-of-pocket cost.
If your health plan has a deductible that hasn't yet been met, you may be responsible for more of the cost until the deductible is satisfied.
Coinsurance and copay requirements may also apply.
Ask about both coverage and estimated patient responsibility when reviewing your benefits. Those are related but aren't the same thing.
Depending on the insurance arrangement and treatment setting, different components of care may be handled differently.
Spravato® treatment involves more than simply receiving a prescription. Administration occurs in an approved healthcare setting, and patients require post-dose monitoring.
This means costs can potentially involve the medication itself as well as clinical services associated with treatment and observation.
Your insurer and treatment provider can explain how these benefits apply to your particular plan.
An initial denial doesn't always mean treatment can never be covered.
Sometimes authorization is denied because additional information or documentation is required. In other situations, the insurer may determine that specific coverage criteria haven't been satisfied.
Depending on the circumstances and insurance plan, there may be opportunities for additional review or appeal.
The appropriate next step depends on the reason for the denial.
Insurance is also an important consideration when comparing Spravato® with IV ketamine for depression.
Spravato® has FDA-approved psychiatric indications and a defined framework for administration and monitoring.
IV ketamine is used by some clinicians for depression, but this use is generally off-label. As a result, patients seeking IV ketamine for depression may encounter different insurance coverage or self-pay arrangements.
This doesn't mean one treatment is automatically better than another. Clinical appropriateness should come first, followed by practical considerations such as availability and insurance benefits.
The manufacturer of Spravato® offers patient-support resources, and some commercially insured patients may qualify for savings assistance subject to program eligibility, limitations, and current terms.
These programs can change, and not every patient qualifies.
Patients should review the current official program requirements rather than assuming a particular discount will apply.
Your treatment provider may also be able to direct you toward relevant resources during the authorization process.
There isn't a guaranteed approval timeline.
Processing time can depend on the insurance company, whether all required documentation has been submitted, and whether the insurer requests additional information.
This is another reason to begin the insurance process before planning your first treatment session.
Providing complete information about previous medications and treatment history can help reduce avoidable delays.
Before your Spravato® evaluation, it can be useful to gather information about your previous depression treatment.
Consider preparing:
Don't worry if you don't remember every detail. Your provider can help determine what information is needed.
Cost is an important part of any healthcare decision, but it shouldn't be evaluated separately from clinical appropriateness.
The first question is whether Spravato® may be an appropriate treatment based on your diagnosis, medical history, previous treatment response, and current needs.
If it is, the next step is determining your insurance benefits and likely financial responsibility.
This allows you to make a decision based on both clinical and practical information.
You don't need to determine your eligibility by yourself.
A psychiatric evaluation can establish whether Spravato® may be appropriate and identify the information necessary for the next steps.
If you've experienced persistent depression despite previous antidepressant treatment, bring as much information about your treatment history as possible to your appointment.
Your provider can then discuss potential options and, when appropriate, begin the insurance authorization process.
Saltmeadow Psychiatry provides Spravato® treatment for eligible adults in Savannah, GA.
Dr. Daniel Perry, MD, MPH evaluates each patient individually, reviewing symptoms, previous antidepressant treatment, medical history, current medications, and other factors before determining whether Spravato® may be appropriate.
Our practice serves patients from Savannah, Pooler, Richmond Hill, Wilmington Island, Effingham County, and surrounding Georgia communities.
If you're considering Spravato® or ketamine therapy in Savannah, GA and want to understand your treatment and insurance options, schedule an evaluation with Saltmeadow Psychiatry.
Saltmeadow Psychiatry
315 Commercial Drive, Suite D-6
Savannah, GA 31406
Phone: (912) 513-2888
Book an Appointment
Many insurance plans may cover Spravato® for eligible patients, but benefits and requirements vary. Coverage should be verified directly for your individual plan.
Many insurers require prior authorization before approving Spravato®. Your plan may request documentation of your diagnosis and previous depression treatments.
There is no single patient price. Your cost can depend on your deductible, copay, coinsurance, coverage, treatment schedule, and other plan provisions.
The next step depends on the reason for the denial. Additional documentation or further review may sometimes be possible, while other denials may relate to eligibility requirements that haven't been met.
Coverage varies, but IV ketamine used specifically for depression is generally an off-label treatment and may be handled differently by insurers than Spravato®.
Insurance benefits and authorization requirements can be reviewed as part of preparing for treatment. Actual coverage and patient responsibility remain subject to the terms and decisions of your insurance plan.
.png)
